-
Something wrong with this record ?
The effect of combined diet containing n-3 polyunsaturated fatty acids and silymarin on metabolic syndrome in rats
M. Poruba, P. Anzenbacher, Z. Racova, O. Oliyarnyk, M. Hüttl, H. Malinska, I. Markova, S. Gurska, L. Kazdova, R. Vecera
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Antioxidants metabolism MeSH
- Diet * MeSH
- Dyslipidemias therapy MeSH
- Gene Expression drug effects MeSH
- Hypertriglyceridemia complications drug therapy genetics MeSH
- Rats MeSH
- Lipids blood MeSH
- Metabolic Syndrome etiology prevention & control MeSH
- Lipid Metabolism drug effects genetics MeSH
- Disease Models, Animal MeSH
- Fatty Acids, Omega-3 administration & dosage MeSH
- Oxidative Stress drug effects MeSH
- Lipid Peroxidation drug effects MeSH
- Rats, Wistar MeSH
- Fish Oils MeSH
- Silymarin administration & dosage MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
The risk of development of metabolic syndrome can be increased by hypertriglyceridemia. A search for effective therapy is a subject of considerable attention. Therefore, our hypothesis is that the fish oil (containing polyunsaturated fatty acids; n-3 PUFA) in a combination with silymarin can more effectively protect against hypertriglyceridemia-induced metabolic disturbances. The study was conducted using a unique non-obese strain of rats with hereditary hypertriglyceridemia an accepted model of metabolic syndrome. Adult male rats were treated with n-3 PUFA (300 mg/kg/day) without or with 1 % micronized silymarin in a diet for 4 weeks. The treatment with the diet containing n-3 PUFA and silymarin significantly reduced concentrations of serum triglycerides (-45 %), total cholesterol (-18 %), non-esterified fatty acids (-33 %), and ectopic lipid accumulation in skeletal muscle (-35 %) compared to controls. In addition, an increase in Abcg5 and Abcg8 mRNA expression (as genes affecting lipid homeostasis) as well as in protein content of ABCG5 (+78 %) and ABCG8 (+232 %) transporters have been determined in the liver of treated rats. Our findings suggest that this combined diet could be used in the prevention of hypertriglyceridemia-induced metabolic disorders.
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21028164
- 003
- CZ-PrNML
- 005
- 20220328134205.0
- 007
- ta
- 008
- 211105s2019 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934322 $2 doi
- 035 __
- $a (PubMed)31755289
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Poruba, Martin $7 xx0230224 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 245 14
- $a The effect of combined diet containing n-3 polyunsaturated fatty acids and silymarin on metabolic syndrome in rats / $c M. Poruba, P. Anzenbacher, Z. Racova, O. Oliyarnyk, M. Hüttl, H. Malinska, I. Markova, S. Gurska, L. Kazdova, R. Vecera
- 504 __
- $a Literatura
- 520 9_
- $a The risk of development of metabolic syndrome can be increased by hypertriglyceridemia. A search for effective therapy is a subject of considerable attention. Therefore, our hypothesis is that the fish oil (containing polyunsaturated fatty acids; n-3 PUFA) in a combination with silymarin can more effectively protect against hypertriglyceridemia-induced metabolic disturbances. The study was conducted using a unique non-obese strain of rats with hereditary hypertriglyceridemia an accepted model of metabolic syndrome. Adult male rats were treated with n-3 PUFA (300 mg/kg/day) without or with 1 % micronized silymarin in a diet for 4 weeks. The treatment with the diet containing n-3 PUFA and silymarin significantly reduced concentrations of serum triglycerides (-45 %), total cholesterol (-18 %), non-esterified fatty acids (-33 %), and ectopic lipid accumulation in skeletal muscle (-35 %) compared to controls. In addition, an increase in Abcg5 and Abcg8 mRNA expression (as genes affecting lipid homeostasis) as well as in protein content of ABCG5 (+78 %) and ABCG8 (+232 %) transporters have been determined in the liver of treated rats. Our findings suggest that this combined diet could be used in the prevention of hypertriglyceridemia-induced metabolic disorders.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antioxidancia $x metabolismus $7 D000975
- 650 12
- $a dieta $7 D004032
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a dyslipidemie $x terapie $7 D050171
- 650 _2
- $a omega-3 mastné kyseliny $x aplikace a dávkování $7 D015525
- 650 _2
- $a rybí oleje $7 D005395
- 650 _2
- $a exprese genu $x účinky léků $7 D015870
- 650 _2
- $a hypertriglyceridemie $x komplikace $x farmakoterapie $x genetika $7 D015228
- 650 _2
- $a metabolismus lipidů $x účinky léků $x genetika $7 D050356
- 650 _2
- $a peroxidace lipidů $x účinky léků $7 D015227
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolický syndrom $x etiologie $x prevence a kontrola $7 D024821
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a silymarin $x aplikace a dávkování $7 D012838
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Anzenbacher, Pavel, $d 1947- $7 xx0034447 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Rácová, Zuzana $7 xx0109661 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Oliyarnyk, Olena $7 xx0095365 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Hüttl, Martina $7 xx0230591 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Malínská, Hana $7 xx0158953 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Marková, Irena $7 xx0161888 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Gurská, Soňa $7 xx0267298 $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Kazdová, Ludmila, $d 1938- $7 xx0053119 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Večeřa, Rostislav, $d 1965- $7 mzk2004236742 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 68, Suppl 1 (2019), s. S39-S50
- 773 0_
- $t 69th Czech-Slovak pharmacological days $g (2019), s. S39-S50 $w MED00208902
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31755289 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20211105 $b ABA008
- 991 __
- $a 20220328134203 $b ABA008
- 999 __
- $a ok $b bmc $g 1728767 $s 1148709
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 68 $c Suppl 1 $d S39-S50 $e 20191122 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- BMC __
- $a 2019 $d S39-S50 $m 69th Czech-Slovak pharmacological days $x MED00208902
- LZP __
- $b NLK118 $a Pubmed-20211105
